PULM 外汇新闻
Pulmatrix Announces Positive Top Line Results In Phase 1 Study With PUR3100 For Acute Migraine
Biopharmaceutical company Pulmatrix, Inc. (PULM) announced Wednesday the successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers for the treatment of acute migraine.
RTTNews
|
763天前
